Compare FNWD & RCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FNWD | RCEL |
|---|---|---|
| Founded | 1994 | N/A |
| Country | United States | United States |
| Employees | N/A | 226 |
| Industry | Savings Institutions | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 140.6M | 126.8M |
| IPO Year | 1996 | N/A |
| Metric | FNWD | RCEL |
|---|---|---|
| Price | $33.39 | $3.94 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 5 |
| Target Price | ★ $37.50 | $7.88 |
| AVG Volume (30 Days) | 6.9K | ★ 209.8K |
| Earning Date | 04-28-2026 | 05-14-2026 |
| Dividend Yield | ★ 1.51% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.52 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $17.40 | $17.17 |
| Revenue Next Year | $5.44 | $49.82 |
| P/E Ratio | $65.75 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $26.46 | $3.22 |
| 52 Week High | $39.99 | $7.12 |
| Indicator | FNWD | RCEL |
|---|---|---|
| Relative Strength Index (RSI) | 59.59 | 43.74 |
| Support Level | $31.24 | $4.00 |
| Resistance Level | $35.27 | $4.09 |
| Average True Range (ATR) | 1.11 | 0.23 |
| MACD | 0.16 | -0.02 |
| Stochastic Oscillator | 70.21 | 26.03 |
Finward Bancorp is a bank holding company that engages in the provision of financial services. It offers products and services related to Personal Banking, Cash Management, Savings Account, ebanking, Wealth Management, and Insurance Services. It is engaged in the business of attracting deposits from the general public and the origination of loans, mostly upon the security of single-family residences and commercial real estate, construction loans, commercial business loans, and municipal loans. Geographically, the activities are carried out throughout the United States. The Company operates as a single reportable segment that derives its revenue mainly from the business of banking.
Avita is largely a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult and paediatric patients in the US and an expanded indication for soft-tissue reconstruction. It is currently used in most of the 140 US burn centers. Despite having product approval in Australia, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region, although international sales, particularly in Japan, are growing. Avita is domiciled, and has its primary listing, in the US.